A Balancing Act: Finding the Right Dose of Pyrazinamide to Treat Tuberculosis.
作者信息
Zavala Sofia, Stout Jason E
机构信息
Department of Medicine Duke University School of Medicine Durham, North Carolina.
出版信息
Am J Respir Crit Care Med. 2024 Dec 1;210(11):1295-1296. doi: 10.1164/rccm.202406-1262ED.
Abstract
摘要
相似文献
1
A Balancing Act: Finding the Right Dose of Pyrazinamide to Treat Tuberculosis.一场平衡行动：找到治疗结核病的合适吡嗪酰胺剂量
Am J Respir Crit Care Med. 2024 Dec 1;210(11):1295-1296. doi: 10.1164/rccm.202406-1262ED.
2
3
A Long-term Co-perfused Disseminated Tuberculosis-3D Liver Hollow Fiber Model for Both Drug Efficacy and Hepatotoxicity in Babies.一种用于评估婴儿药物疗效和肝毒性的长期共灌注播散性肺结核-3D肝脏中空纤维模型
EBioMedicine. 2016 Apr;6:126-138. doi: 10.1016/j.ebiom.2016.02.040. Epub 2016 Feb 27.
4
Pyrazinamide blood concentrations in children suffering from tuberculosis: a comparative study at two doses.患有结核病儿童的吡嗪酰胺血药浓度：两种剂量的对比研究
Br J Clin Pharmacol. 2008 Mar;65(3):423-7. doi: 10.1111/j.1365-2125.2007.03069.x. Epub 2007 Dec 17.
5
Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial.贝达喹啉、莫西沙星、普托马尼和吡嗪酰胺治疗药物敏感或耐药性肺结核患者的前 8 周：一项多中心、开放标签、部分随机、2b 期临床试验。
Lancet Respir Med. 2019 Dec;7(12):1048-1058. doi: 10.1016/S2213-2600(19)30366-2. Epub 2019 Nov 12.
6
Dose-dependent activity of pyrazinamide in animal models of intracellular and extracellular tuberculosis infections.吡嗪酰胺在细胞内和细胞外结核感染动物模型中的剂量依赖性活性。
Antimicrob Agents Chemother. 2011 Apr;55(4):1527-32. doi: 10.1128/AAC.01524-10. Epub 2011 Jan 31.
7
High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial.高剂量利福平、莫西沙星和SQ109治疗结核病：一项多组、多阶段随机对照试验。
Lancet Infect Dis. 2017 Jan;17(1):39-49. doi: 10.1016/S1473-3099(16)30274-2. Epub 2016 Oct 26.
8
Enhanced bactericidal activity of rifampin and/or pyrazinamide when combined with PA-824 in a murine model of tuberculosis.在小鼠结核病模型中，利福平及/或吡嗪酰胺与PA-824联合使用时杀菌活性增强。
Antimicrob Agents Chemother. 2008 Oct;52(10):3664-8. doi: 10.1128/AAC.00686-08. Epub 2008 Aug 11.
9
Pyrazinamide Is Active against Mycobacterium tuberculosis Cultures at Neutral pH and Low Temperature.吡嗪酰胺在中性pH值和低温条件下对结核分枝杆菌培养物具有活性。
Antimicrob Agents Chemother. 2016 Jul 22;60(8):4956-60. doi: 10.1128/AAC.00654-16. Print 2016 Aug.
10
Optimizing Dosing and Fixed-Dose Combinations of Rifampicin, Isoniazid, and Pyrazinamide in Pediatric Patients With Tuberculosis: A Prospective Population Pharmacokinetic Study.优化利福平、异烟肼和吡嗪酰胺在儿童结核病患者中的剂量和固定剂量组合：一项前瞻性群体药代动力学研究。
Clin Infect Dis. 2022 Aug 24;75(1):141-151. doi: 10.1093/cid/ciab908.
本文引用的文献
1
Pyrazinamide Safety, Efficacy, and Dosing for Treating Drug-Susceptible Pulmonary Tuberculosis: A Phase 3, Randomized Controlled Clinical Trial.吡嗪酰胺治疗药物敏感肺结核的安全性、疗效和剂量：一项 3 期随机对照临床试验。
Am J Respir Crit Care Med. 2024 Dec 1;210(11):1358-1369. doi: 10.1164/rccm.202401-0165OC.
2
Novel Regimens of Bedaquiline-Pyrazinamide Combined with Moxifloxacin, Rifabutin, Delamanid and/or OPC-167832 in Murine Tuberculosis Models.贝达喹啉-吡嗪酰胺联合莫西沙星、利福布丁、德拉马尼和/或 OPC-167832 治疗小鼠结核病模型的新方案。
Antimicrob Agents Chemother. 2022 Apr 19;66(4):e0239821. doi: 10.1128/aac.02398-21. Epub 2022 Mar 22.
3
Optimising pyrazinamide for the treatment of tuberculosis.优化吡嗪酰胺治疗结核病。
Eur Respir J. 2021 Jul 20;58(1). doi: 10.1183/13993003.02013-2020. Print 2021 Jul.
4
Drug Exposure and Minimum Inhibitory Concentration Predict Pulmonary Tuberculosis Treatment Response.药物暴露和最小抑菌浓度可预测肺结核治疗反应。
Clin Infect Dis. 2021 Nov 2;73(9):e3520-e3528. doi: 10.1093/cid/ciaa1569.
5
Pharmacokinetics of Pyrazinamide and Optimal Dosing Regimens for Drug-Sensitive and -Resistant Tuberculosis.吡嗪酰胺的药代动力学与敏感及耐药结核病的最佳给药方案。
Antimicrob Agents Chemother. 2017 Jul 25;61(8). doi: 10.1128/AAC.00490-17. Print 2017 Aug.
6
Feasibility of a fixed-dose regimen of pyrazinamide and its impact on systemic drug exposure and liver safety in patients with tuberculosis.固定剂量吡嗪酰胺方案的可行性及其对结核病患者全身药物暴露和肝脏安全性的影响。
Antimicrob Agents Chemother. 2012 Nov;56(11):5442-9. doi: 10.1128/AAC.05988-11. Epub 2012 Jul 9.
7
Clinical and toxicodynamic evidence that high-dose pyrazinamide is not more hepatotoxic than the low doses currently used.临床和毒动学证据表明，高剂量吡嗪酰胺的肝毒性并不比目前使用的低剂量更严重。
Antimicrob Agents Chemother. 2010 Jul;54(7):2847-54. doi: 10.1128/AAC.01567-09. Epub 2010 May 3.
8
Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana.博茨瓦纳主要为感染艾滋病毒的成年结核病患者队列中异烟肼、利福平、乙胺丁醇和吡嗪酰胺的药代动力学及治疗结果
Clin Infect Dis. 2009 Jun 15;48(12):1685-94. doi: 10.1086/599040.
9
Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis.活动性结核病患者中一线抗结核药物严重副作用的发生率。
Am J Respir Crit Care Med. 2003 Jun 1;167(11):1472-7. doi: 10.1164/rccm.200206-626OC. Epub 2003 Jan 31.
10
USPHS Tuberculosis Short-Course Chemotherapy Trial 21: effectiveness, toxicity, and acceptability. The report of final results.美国公共卫生署结核病短程化疗试验21：疗效、毒性及可接受性。最终结果报告。
Ann Intern Med. 1990 Mar 15;112(6):397-406. doi: 10.7326/0003-4819-76-3-112-6-397.
Zotero 插件